Strong and convincing evidence has emerged from a new scientific study that proves psychedelic drugs have the potential to treat mental health problems when consumed in micro doses.
Study confirms decade-old suspicions
During the study, University of California researchers exposed neurons (from humans, rats and other animals) to a range of psychedelic drugs including MDMA, psilocin (found in magic mushrooms) and LSD.
The lab-cultivated neurons used were from the prefrontal cortex – the part of the brain associated with the development of some mental illnesses.
Here’s what they discovered:
- The majority of the psychedelics tested promoted new dendrite growth. Dendrites help send information from other neurons to the cell, and are pretty important in terms of brain function.
- The affected neurons also experienced increased dendritic spine density. Dendritic spines store synaptic strength and help transmit signals.
- The microdoses also helped new connections (synapses) between neurons grow.
These findings (published in Cell Reports) confirm long-held beliefs that micro doses of psychedelic drugs can actually repair the brain’s circuitry and function, improving plasticity and undoing damage caused by stress and trauma.
A medical breakthrough looms large.
Rebranding psychedelic drugs
Scientists are now realising the importance of rebranding psychedelic drugs.
The research team behind this study even wants to rename the drugs as “psychoplastogens”, and their intent is understandable.
By erasing the stigma associated with psychedelic drugs, researchers can secure the funding and government support needed to make the sort of breakthroughs that offer patients suffering from various mental health problems safer and more effective alternatives.
Who knows, maybe twenty years from now psychedelic drugs may no longer be known as party drugs, but as cures.